The National Health Service (Pharmaceutical Services) (Wales) (Miscellaneous Amendments) Regulations 2025

Type Welsh-Statutory-Instrument
Publication 2025-03-05
State In force
Jurisdiction Wales
Department King's Printer of Acts of Parliament
Reform history JSON API PDF

Made: 5 March 2025

Laid before Senedd Cymru: 7 March 2025

Coming into force in accordance with regulation 1(2) and (3)

The Welsh Ministers, in exercise of the powers conferred on them by sections 15, 80, 104 and 203(9) and (10) of the National Health Service (Wales) Act 2006[^f00001], make the following Regulations.

Title and coming into force

1

Amendments to the National Health Service (Pharmaceutical Services) (Wales) Regulations 2020

2
  • Prescription only medicine” (“meddyginiaeth a roddir ar bresgripsiwn yn unig”) means a medicine referred to in regulation 5(3) (classification of medicinal products) of the Human Medicines Regulations 2012;

, and

(4) The NHS pharmacist must, in appropriate cases, keep and maintain a record of any advice given and any interventions or referrals made (in particular of clinically significant interventions) under this paragraph.

Amendments to the National Health Service (Pharmaceutical Services) (Wales) (Amendment) Regulations 2024

3

Signed

Jeremy Miles — Cabinet Secretary for Health and Social Care, one of the Welsh Ministers — 5 March 2025

Explanatory note

(This note is not part of the Regulations)

EXPLANATORY NOTE

These Regulations amend two sets of Regulations which make provision about, and in connection with, pharmaceutical services.

Regulation 2 amends the National Health Service (Pharmaceutical Services) (Wales) Regulations 2020 and regulation 3 amends the National Health Service (Pharmaceutical Services) (Wales) (Amendment) Regulations 2024.

The Welsh Ministers’ Code of Practice on the carrying out of Regulatory Impact Assessments was considered in relation to these Regulations. As a result, it was not considered necessary to carry out a regulatory impact assessment as to the likely costs and benefits of complying with these Regulations.

Footnotes

[^f00001]: 2006 c. 42.

[^f00002]: S.I. 2020/1073 (W. 241), amended by S.I. 2024/1196 (W. 196); there are other amending instruments, but none are relevant.

[^f00003]: Paragraph 5A inserted by S.I. 2024/1196 (W. 196).

[^f00004]: Paragraph 9(8C)(b) inserted by S.I. 2024/1196 (W.196).

[^f00005]: Paragraph 20(4) substituted by S.I. 2024/1196 (W. 196).

[^f00006]: Paragraph 23(6B) inserted by S.I. 2024/1196 (W. 196).

[^f00007]: S.I. 2024/1196 (W. 196).

Editorial notes

[^key-fa41722551b6b8e0439efc282932dd68]: Reg. 1 in force at 31.3.2025, see reg. 1(2)

[^key-dc656ce43b8a36f5dbecfe42bf6bb579]: Reg. 2 in force at 1.4.2025 at 12.01 a.m., see reg. 1(3)

[^key-ae3cdcb0f01d552f6008cc844f709653]: Reg. 3 in force at 31.3.2025, see reg. 1(2)

Enwi a dod i rym

Diwygio Rheoliadau’r Gwasanaeth Iechyd Gwladol (Gwasanaethau Fferyllol) (Cymru) 2020

Diwygio Rheoliadau’r Gwasanaeth Iechyd Gwladol (Gwasanaethau Fferyllol) (Cymru) (Diwygio) 2024

Reading this document does not replace reading the official text published on legislation.gov.uk. Contains public sector information licensed under the Open Government Licence v3.0. We assume no responsibility for any inaccuracies arising from the conversion of the original CLML XML to this format.